News: Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

1,727.00GBp
29 Aug 2014
Price Change (% chg)

21.00p (+1.23%)
Prev Close
1,706.00p
Open
1,720.00p
Day's High
1,734.00p
Day's Low
1,705.00p
Volume
193,848
Avg. Vol
228,384
52-wk High
1,835.00p
52-wk Low
1,006.59p

Search Stocks
Select another date:

Wed, Aug 20 2014

UPDATE 2-Hikma Pharma cuts revenue forecast for branded drugs

* Revenue in injectibles business rises 41 pct to $346 mln

Hikma first-half profit jumps on strong injectibles sales

Aug 20 - Hikma Pharmaceuticals Plc reported a 44 percent rise in first-half adjusted profit, helped by strong demand for its high-margin injectibles particularly in the United States.

BRIEF-Hikma Pharma to buy Ben Venue's generic injectables factory

* Agreed with Ben Venue Laboratories, Inc. , part of Boehringer Ingelheim Group of companies, to acquire their generic injectables manufacturing site in Bedford, Ohio

Emerging market fund managers ignore borders, chase profits

BOSTON - U.S. emerging market fund managers are paying less attention to where a company is located or listed than to whether it's making money, either as an advanced world company doing business in the developing world, or the other way around.

BRIEF-Hikma buys assets of Bedford Laboratories for $300 mln

* Signed an asset purchase agreement with Ben Venue Laboratories Inc., a member of Boehringer Ingelheim Group of Companies

BRIEF-Hikma raises operating margin forecast for injectables unit

* Has made a strong start to year and pleased to be reiterating guidance for 2014 of around 5 pct group revenue growth

UPDATE 1-Hikma full-year profit doubles on strong doxycycline sales

* Expects injectibles revenue to rise 20 percent this year

Hikma full-year profit doubles on strong doxycycline sales

March 12 - Hikma Pharmaceuticals Plc's full-year profit more than doubled helped by strong demand and higher prices for the antibiotic doxycycline that is used in the treatment bacterial infections including Lyme disease.

BRIEF-Hikma appoints Mazen Darwazah CEO of MENA, Emerging Markets

March 12 - Hikma Pharmaceuticals PLC : * Mazen Darwazah is to be promoted to the new position of president and CEO of MENA and Emerging Markets * Source text for Eikon: * For more news, please click here

BRIEF-Hikma Pharmaceuticals expects 5 pct revenue growth in 2014

March 12 - Hikma Pharmaceuticals PLC : * In 2014, expect revenue growth of 5 pct * Final dividend $0.13/shr * Total dividend $0.20/shr * Group FY revenue increased 23 pct to $1,365 million * FY adjusted operating margin rose to 30.3 pct from 17.5 pct, reflecting significant improvement in generics and injectables margins * FY profit attributable to shareholders increased 112 pct to $212 million * On adjusted basis, profit attributable to shareholders rose 128% to $274 million

Select another date:
Search Stocks